Browse drugs

…ansen JS, Larsen FO, Theile S, Hasselby JP, Willemoe GL, et al. Nivolumab with or without ipilimumab combined with stereotactic body radi…

…histology-specific platinum doublet chemotherapy, combined with ipilimumab (1 mg/kg every 6 weeks) and nivolumab (360 mg every 3 weeks), f…

…vec (RP1; an HSV-1-based oncolytic immunotherapy) combined with nivolumab demonstrated clinically meaningful, durable antitumor activity …

…t-remission, one of whom achieved CR after salvage therapy with nivolumab. Among the 4 patients who were treated with relatlimab and nivo…

…ypically delivered 5 days a week over 7 weeks concurrently with cisplatin, a regimen established through multiple randomised trials, demo…

…ed immune content. This study evaluated whether the addition of nivolumab to SOC was associated with improved disease control in patients…

…horter PFS among patients with metastatic ccRCC treated with 1L nivolumab+ipilimumab. These findings support the concept that host body c…

…rs.Methods DART is a multicenter, multicohort phase II trial of ipilimumab (1 mg/kg intravenously every 6 weeks) plus nivolumab (240 mg in…

…e target for nivolumab, in CRC (n=4), RCC (n=2) and CaBr (n=3), Nivolumab treatment induced increase in proportion of activated effector …

… with an objective response.Conclusions mKRAS-VAX combined with ipilimumab and nivolumab was well-tolerated and resulted in clinical respo…

…receiving durvalumab, 25% receiving cemiplimab, 66.7% receiving avelumab, and 60% receiving the ipilimumab and nivolumab. A 61.5% of irA…

…ring may help identify patients who could benefit from extended osimertinib therapy, although further clinical validation is warranted.ctDN…